US4062936A - Carrier for immunochemical measurement - Google Patents
Carrier for immunochemical measurement Download PDFInfo
- Publication number
- US4062936A US4062936A US05/628,344 US62834475A US4062936A US 4062936 A US4062936 A US 4062936A US 62834475 A US62834475 A US 62834475A US 4062936 A US4062936 A US 4062936A
- Authority
- US
- United States
- Prior art keywords
- blood cells
- carrier
- tannic acid
- immunochemical
- bound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000005259 measurement Methods 0.000 title claims abstract description 37
- 230000000984 immunochemical effect Effects 0.000 title claims abstract description 35
- 210000000601 blood cell Anatomy 0.000 claims abstract description 103
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims abstract description 77
- 239000001263 FEMA 3042 Substances 0.000 claims abstract description 77
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims abstract description 77
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical group OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims abstract description 77
- 229940033123 tannic acid Drugs 0.000 claims abstract description 77
- 235000015523 tannic acid Nutrition 0.000 claims abstract description 77
- 229920002258 tannic acid Polymers 0.000 claims abstract description 77
- 238000006243 chemical reaction Methods 0.000 claims description 55
- 230000004520 agglutination Effects 0.000 claims description 37
- 239000007853 buffer solution Substances 0.000 claims description 30
- 239000000243 solution Substances 0.000 claims description 27
- 239000000427 antigen Substances 0.000 claims description 26
- 102000036639 antigens Human genes 0.000 claims description 26
- 108091007433 antigens Proteins 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 17
- 239000008363 phosphate buffer Substances 0.000 claims description 14
- 230000005764 inhibitory process Effects 0.000 claims description 9
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- 239000006285 cell suspension Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000003381 stabilizer Substances 0.000 claims description 5
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 230000001235 sensitizing effect Effects 0.000 claims description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960002319 barbital Drugs 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 2
- 239000012266 salt solution Substances 0.000 claims description 2
- AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000035945 sensitivity Effects 0.000 description 20
- 239000000725 suspension Substances 0.000 description 15
- 239000000969 carrier Substances 0.000 description 12
- 239000012050 conventional carrier Substances 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 229940098773 bovine serum albumin Drugs 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000003127 radioimmunoassay Methods 0.000 description 7
- 238000004062 sedimentation Methods 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 108010074605 gamma-Globulins Proteins 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 108010067755 dinitrophenyl-bovine serum albumin Proteins 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000473945 Theria <moth genus> Species 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- VILFTWLXLYIEMV-UHFFFAOYSA-N 1,5-difluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(F)C=C1F VILFTWLXLYIEMV-UHFFFAOYSA-N 0.000 description 1
- HVYWMOMLDIMFJA-UHFFFAOYSA-N 3-cholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 HVYWMOMLDIMFJA-UHFFFAOYSA-N 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 241000269350 Anura Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 241001125840 Coryphaenidae Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 241000270722 Crocodylidae Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102100021022 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- XUGUHTGSMPZQIW-UHFFFAOYSA-N [[4-(4-diazonioiminocyclohexa-2,5-dien-1-ylidene)cyclohexa-2,5-dien-1-ylidene]hydrazinylidene]azanide Chemical compound C1=CC(N=[N+]=[N-])=CC=C1C1=CC=C(N=[N+]=[N-])C=C1 XUGUHTGSMPZQIW-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003023 adrenocorticotropic effect Effects 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229910052622 kaolinite Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
- G01N33/555—Red blood cell
- G01N33/556—Fixed or stabilised red blood cell
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/823—Immunogenic carrier or carrier per se
Definitions
- the RIA method is unsuitable for measuring components of the human body as a matter of daily routine in general medical institutions, since it requires special instruments utilizing isotopes and the operation thereof is complicated and inconvenient.
- a well known simple method for measuring biological components of the human body has comprised sensitizing a carrier composed of blood cells, polystyrene latex, kaolinite, bentonite, active charcoal, crystalline cholesterin, and the like with an antigen or antibody, and then reacting the carrier with the antibody or antigen present in the sample and causing an immunochemical agglutination reaction or an agglutination inhibition reaction.
- a method using blood cells as the carrier is much preferred because of its high sensitivity.
- the blood cell used as a carrier for the abovementioned immunochemical measurement is usually prepared from blood cells obtained from various animals without any chemical treatment or blood cells first treated with an appropriate fixing agent such as formaldehyde, pyruvinaldehyde, hydrogen peroxide, or the like, and then treated with a binding agent such as tannic acid, bisdiazobenzidine, 1,3-difluoro-4,6-dinitrobenzene or the like.
- an appropriate fixing agent such as formaldehyde, pyruvinaldehyde, hydrogen peroxide, or the like
- a binding agent such as tannic acid, bisdiazobenzidine, 1,3-difluoro-4,6-dinitrobenzene or the like.
- the animals from which the blood cell is obtained are generally mammals, e.g. cattle, horses, sheep, rabbits, humans, etc. or birds, e.g. chicken, pigeons, turkeys, etc., though other animals including reptiles such as crocodiles and snakes and amphibians such as frogs, etc., and marine animals such as dolphins may also be used.
- the blood cell obtained from these animals can be used in its untreated state, in most cases, a fixed blood cell, treated with the above mentioned fixing agent is used because an untreated blood cell has poor strength in its natural form tending to hemolyze during mechanical or chemical treatments.
- blood cells in this specification means the material component in the blood consisting mainly of red blood cells which includes untreated blood cells without any treatment and the said fixed blood cells.
- the quantity of blood cells is represented by the apparent volume of blood cells obtained by the centrifugation of blood.
- blood cells have to be treated with the binding agent as mentioned above before they are used as a carrier. It is hard to bind antigens or antibodies to blood cells which are not treated with the binding agent and even if they are bound, no uniform product can be obtained, resulting in failure to obtain a carrier having a stable sensitivity.
- a blood cell treated with a binding agent exhibits improved bonding power on the surface of the blood cell enhancing the binding to the antigen or antibody, so that a carrier with a better immunochemical agglutination reaction or agglutination inhibition reaction is obtained.
- tannic acid when used as a binding agent according to the conventional method, a suspension of blood cells in a buffer solution (blood cell concentration 2 to 8%) is mixed with an equal volume of a solution of binding agent in the said buffer solution and both components are allowed to react at 37° to 56° C for 30 to 60 minutes.
- the said solution of tannic acid is usually a concentration of 1/20,000 to 1/40,000, the representation 1/20,000 of said tannic acid solution indicates that the 20,000 ml solution was prepared by adding 1 g of the solute to the solvent. Other cases follow suit.
- tannic acid As above, if blood cells are treated with tannic acid, about 0.3 to 2.5 mg of tannic acid is bound to 1 ml of blood cells.
- the blood cells have a sensitivity of about 100 ng/ml in the measurement of human serum albumin (hereinafter referred to as HSA) with the blood cells as a carrier.
- HSA human serum albumin
- This value of sensitivity is comparatively high as compared with that with other types of carriers, such as the fine particles of polystyrene latex, other than the blood cells. Nevertheless, the value is no more than 1/10 to 1/10,000 as compared with the sensitivity of the RIA method.
- the carrier should have the following properties: when the carrier is sensitized with an antigen or antibody corresponding to the object substance of the measurement, any slight quantity of antigen or antibody present in a living body as biological components can readily bring about an immunochemical reaction with the antibody or antigen with which the carrier was sensitized and, based on this reaction, the sensitized carrier undergoes a complete agglutination reaction; however, in the event that the immunochemical reaction does not take place, no spontaneous agglutination occurs.
- the object of the present invention is to provide a carrier which, in a simplified measurement of biological components based on the utilization of an immunochemical agglutination reaction or an agglutination inhibition reaction, gives a high sensitivity and specificity comparable to that of Radioimmunoassay.
- the present invention relates to a carrier for immunochemical measurement characterized in that tannic acid is bound to blood cells in a proportion of 30 to 500 mg per 1 ml of blood cells.
- tannic acid is bound to blood cells in a proportion of 30 to 500 mg per 1 ml of blood cells.
- immunochemical reactions were quite simple as compared with radioimmunoassay (RIA method), they have drawbacks in that an antigen-antibody reaction has produced a low sensitivity and specificity as compared with the said RIA method because no one could find a suitable carrier for carrying antigen and antibody which reacts with biological components through an immunochemical reaction.
- the carrier of the present invention is usually prepared by mixing and reacting a blood cell suspension containing 2 to 4% blood cells in a buffer solution with a solution of tannic acid in the said buffer solution at a concentration of 1/50 to 1/1,000 tannic acid, so that 30 to 500 mg of tannic acid is bound to 1 ml of the blood cells.
- the blood cells used in the present invention may be of any type which has been used as a carrier for conventional immunochemical measurements.
- the quantity of tannic acid to be bound to blood cells is preferably in the range of 30 to 500 mg per 1 ml of the blood cells. If the quantity is less than 30 mg, the carrier cannot achieve the desired high sensitivity and specificity. If it exceeds 500 mg, the carrier has too intense an agglutination property to be controlled by the method hereinafter described, and therefore the carrier can no longer be used in an immunochemical measurement.
- the buffer solution to suspend blood cells and dissolve tannic acid may be any type of buffer solution conventionally used in an immunochemical reaction, and moreover, a physiological saline solution can be used, preferably a phosphate-buffer saline solution.
- the blood cells may be reacted with tannic acid at room temperature, better results are obtained by heating at a temperature ranging from 37° to 56° C, which is the usual temperature range adopted in general immunochemical processes.
- the present carrier retaining a larger quantity of tannic acid than the conventional carriers, the agglutination property of the carrier itself is much enhanced and at the same time, it can bind a larger quantity of antigen or antibody to itself than the conventional carriers.
- Table 1 The values shown in Table 1 are those of tannic acid measured with Folin-Denis reagent in ethanol extracts from the blood cells treated with tannic acid. About the same values are also obtained by measuring the residual tannic acid content in the supernatant after the blood cells are bound with tannic acid and deducing it from the initial quantity of tannic acid. From this table, a majority of the added tannic acid is found to be bound to blood cells regardless of the quantity of tannic acid added to blood cells.
- the agglutination property of a carrier itself generally varies with pH and ionic strength, etc., of the buffer solution in which the carrier is suspended.
- carriers bound with various quantities of tannic acid are suspended in a phosphate buffer saline solution (pH 6.4 and concentration 0.076 Mol) at a concentration of 0.133%, and 0.5 ml of each suspension is placed in a small test tube and allowed to stand for two hours, after which the agglutination property of the carrier is evaluated on the basis of the sedimentation patterns at the bottom of the tube.
- a phosphate buffer saline solution pH 6.4 and concentration 0.076 Mol
- the agglutination property of a carrier itself, with the addition of bovine serum albumin as a stabilizer for a reaction system, is measured in the same manner as in the absence of the serum albumin, except that a phosphate-buffer saline solution containing 0.2% bovine serum albumin is used for suspending the carrier.
- the agglutination property of a carrier sensitized with an anti-HSA antibody is measured in the same manner as in Column 2 of Table 2, except that the carrier sensitized with the anti-HSA antibody is used.
- the criteria for sedimentation patterns at the bottom of a test tube are set according to the following:
- Table 2 shows that the carrier of the present invention bound with a large quantity of tannic acid brings about a spontaneous agglutination reaction, while the conventional carriers bound with only a small quantity of tannic acid do not. This suggests that the bonding of blood cells with a large quantity of tannic acid leads to occurrence of a certain change on the surface of blood cells which brings about an increase in the agglutination property of the carrier itself.
- the quantity of antibody or antigen bound to a carrier is measured through determination of the quantity of antibody or antigen remaining in the supernatant after the sensitization of the carrier with antibody or antigen by an immunological diffusion method, and deducing it from the initial quantity of antibody or antigen added for the purpose of sensitization.
- a rabbit gamma globulin and HSA are respectively used as antibody and antigen.
- the carrier of the present invention has a remarkably increased potency to bind antibody or antigen as compared with the conventional carriers.
- the carrier of the present invention has the advantage that the high agglutination property and potency to bind a large quantity of antigen or antibody can be controlled in accordance with the purpose of application.
- control is most effectively made in applying the known art most advantageously, e.g., in the sensitization of a carrier with antigen or antibody so as to control the quantity of antigen or antibody, the addition of normal rabbit albumin, bovine serum albumin or a surfactant etc. as stabilizer for the immunochemical reaction system, the control of pH and ionic strength of the immunochemical reaction system, or the combination of this well known art. (See Table 2)
- the carrier of the present invention can be used as a carrier for antigen or antibody in the immunochemical agglutination and agglutination inhibition reactions.
- HSA is measured by using the present carrier
- the measurement of 100 pg/ml order of HSA is possible. That is to say, the sensitivity of the measurement is enhanced about 1,000 times as compared with the use of conventional carriers.
- each of the sensitized carriers thus obtained was washed with 50 ml of buffer solution, and prepared into a 1% suspension in a phosphate buffer saline solution containing 10% of sucrose, 0.1% of bovine serum albumin and 0.02% of normal rabbit serum.
- 0.1 ml of each of the sensitized carrier suspensions was placed in a test tube of an inner diameter of about 9mm having a hemispherical bottom and mixed gradually with 0.3 ml of the phosphate buffer saline solution to give a 0.25% suspension, followed by the additions of 0.1 ml of HSA solutions respectively with 0.05, 0.1, 0.2, 0.5, 1.0, 2.0, 5.0 10, 20, 50 or 100 ng/ml of HSA. After shaking, the mixtures were allowed to stand for 2 hours. The sedimentation patterns developed at the bottom of the test tubes were observed, and the results were judged as negative and positive respectively according to whether a sedimentation ring was formed or not.
- Table 4 illustrates the results of sensitivities of various carriers exhibited in the HSA measurements as represented in terms of the minimum quantities of HSA necessary for giving positive reactions.
- each of the carrier suspensions prepared in the same manner as in Experiment 1 was mixed with a solution of 6 mg of 2,4-dinitrophenol-bovine serum albumin combination product (hereinafter referred to as DNP-BSA) in 60 ml of phosphate buffer saline solution, and the solution was reacted at 56° C for 30 minutes until the carrier was sensitized with DNP-BSA. Then each of the carriers was washed with 50 ml of the above-mentioned buffer solution and prepared into 1% suspension in the phosphate buffer saline solution containing 10% of sucrose, 0.1% of bovine serum albumin and 0.02% of normal rabbit serum.
- DNP-BSA 2,4-dinitrophenol-bovine serum albumin combination product
- An anti-DNP-BSA anti-serum was prepared by mixing Freund's Complete Adjuvant with DNP-BSA by a conventional method and thereby immunizing rabbits. The absorption of the serum with BSA yielded an anti-serum which exhibited an antibody activity only to DNP.
- the anti-serum was diluted with 0.25% saline solution containing 1% BSA in the order of 1, 10, 20, 50, 100, 200, 300, 400, and 500 times. Then, 0.1 ml of the diluted serums was added to a test tube which contained 0.1 ml of each of the said sensitized carrier suspensions and 0.3 ml of phosphate buffer saline solution and shaken. After allowing to stand for 2 hours, the maximum dilution ratio of anti-serum necessary for the occurrence of an agglutination reaction of the carriers was determined.
- 0.1 ml of the said anti-serum of maximum dilution was mixed in a test tube with 0.1 ml of a DNP solution containing 50, 100, 200, 300, 500, 700 or 1,000 ng/ml of DNP in phosphate buffer saline solution, to which were added 0.1 ml of said sensitized carrier suspension and 0.2 ml of phosphate buffer saline solution. After shaking and allowing to stand for 2 hours, the sedimentation pattern developed on the bottom of the test tube was observed. In the case of a sedimentation ring being formed, the result was judged as positive, while it was judged as negative when a sedimentation ring was not formed.
- the sensitivities of the carriers are summarized in Table 5, being represented in terms of the minimum quantities of DNP necessary for the occurrence of positive reactions.
- the carrier of the present invention bound with 100 mg tannic acid per 1 ml of blood cell can bring about an agglutination reaction with the anti-serum diluted three hundred fold.
- the carrier of the present invention exhibited 5 to 10 times higher sensitivity in the measurement than the conventional carriers.
- the said blood cell suspension was mixed with 2,000 ml of a tannic acid solution of 1/350 concentration and the mixture was reacted at 25° C for 60 minutes. After the reaction the carrier was washed with 1,000 ml of the said solvent. The carrier in this Example was bound with about 100 mg of tannic acid per 1 ml of blood cells.
- the carrier in this Example has about 30 mg of tannic acid per 1 ml of blood cells.
- the said blood suspension was mixed with a solution of tannic acid 1/50 concentration dissolved in the said buffer solution, and the mixture was reacted at 56° C for 30 minutes. After the reaction, the product was washed with the said buffer solution to give a carrier.
- the carrier in this Example contains about 500 mg of tannic acid per 1 ml of blood cells.
- the carrier of the present invention for immunochemical measurements has a higher sensitivity and higher specificity as compared with conventional carriers so that it easily brings about an immunochemical reaction even when the quantity of biological components is very small, and based on this reaction, it shows a complete agglutination reaction. Therefore, the use of the carrier of the present invention facilitates the measurement of biological components affording itself a very high medical value.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Carrier for immunochemical measurement wherein tannic acid is bound to blood cells in the proportion of 30 to 500 mg per milliliter of the blood cells.
Description
In recent years, the measurement of biologically active components in a living body, such as insulin, growth hormones, prolactin, gastrin, adrenocorticotrophic hormones, thyroid hormones, angiotensin, and the like, has been recognized as having important significance in the diagnosis, therapy, and prevention of human diseases or in various functional tests. As a result, such measurements have recently come to be carried out very frequently.
However, as all these biological components are present in very small quantities, they cannot be measured by a conventional chemical method and are measured by an immunochemical method, such as by a radioimmunoassay (hereinafter referred to as RIA) which enables extraordinarily highly sensitive measurement.
However, the RIA method is unsuitable for measuring components of the human body as a matter of daily routine in general medical institutions, since it requires special instruments utilizing isotopes and the operation thereof is complicated and inconvenient.
Heretofore, a well known simple method for measuring biological components of the human body has comprised sensitizing a carrier composed of blood cells, polystyrene latex, kaolinite, bentonite, active charcoal, crystalline cholesterin, and the like with an antigen or antibody, and then reacting the carrier with the antibody or antigen present in the sample and causing an immunochemical agglutination reaction or an agglutination inhibition reaction. Particularly, a method using blood cells as the carrier is much preferred because of its high sensitivity.
The blood cell used as a carrier for the abovementioned immunochemical measurement is usually prepared from blood cells obtained from various animals without any chemical treatment or blood cells first treated with an appropriate fixing agent such as formaldehyde, pyruvinaldehyde, hydrogen peroxide, or the like, and then treated with a binding agent such as tannic acid, bisdiazobenzidine, 1,3-difluoro-4,6-dinitrobenzene or the like.
The animals from which the blood cell is obtained are generally mammals, e.g. cattle, horses, sheep, rabbits, humans, etc. or birds, e.g. chicken, pigeons, turkeys, etc., though other animals including reptiles such as crocodiles and snakes and amphibians such as frogs, etc., and marine animals such as dolphins may also be used.
Although the blood cell obtained from these animals can be used in its untreated state, in most cases, a fixed blood cell, treated with the above mentioned fixing agent is used because an untreated blood cell has poor strength in its natural form tending to hemolyze during mechanical or chemical treatments.
The term "blood cells" in this specification means the material component in the blood consisting mainly of red blood cells which includes untreated blood cells without any treatment and the said fixed blood cells. The quantity of blood cells is represented by the apparent volume of blood cells obtained by the centrifugation of blood.
These blood cells have to be treated with the binding agent as mentioned above before they are used as a carrier. It is hard to bind antigens or antibodies to blood cells which are not treated with the binding agent and even if they are bound, no uniform product can be obtained, resulting in failure to obtain a carrier having a stable sensitivity. On the other hand, a blood cell treated with a binding agent exhibits improved bonding power on the surface of the blood cell enhancing the binding to the antigen or antibody, so that a carrier with a better immunochemical agglutination reaction or agglutination inhibition reaction is obtained. For instance, when tannic acid is used as a binding agent according to the conventional method, a suspension of blood cells in a buffer solution (blood cell concentration 2 to 8%) is mixed with an equal volume of a solution of binding agent in the said buffer solution and both components are allowed to react at 37° to 56° C for 30 to 60 minutes. The said solution of tannic acid is usually a concentration of 1/20,000 to 1/40,000, the representation 1/20,000 of said tannic acid solution indicates that the 20,000 ml solution was prepared by adding 1 g of the solute to the solvent. Other cases follow suit.
As above, if blood cells are treated with tannic acid, about 0.3 to 2.5 mg of tannic acid is bound to 1 ml of blood cells. The blood cells have a sensitivity of about 100 ng/ml in the measurement of human serum albumin (hereinafter referred to as HSA) with the blood cells as a carrier. This value of sensitivity is comparatively high as compared with that with other types of carriers, such as the fine particles of polystyrene latex, other than the blood cells. Nevertheless, the value is no more than 1/10 to 1/10,000 as compared with the sensitivity of the RIA method.
Accordingly, in immunochemical agglutination reactions or agglutination inhibition reactions, it is impossible to obtain a sensitivity comparable to that of a RIA method by using a conventional carrier. In other words, the measurement of such high sensitivity required a novel carrier.
As a highly sensitive and highly specific carrier used for an immunochemical measurement the carrier should have the following properties: when the carrier is sensitized with an antigen or antibody corresponding to the object substance of the measurement, any slight quantity of antigen or antibody present in a living body as biological components can readily bring about an immunochemical reaction with the antibody or antigen with which the carrier was sensitized and, based on this reaction, the sensitized carrier undergoes a complete agglutination reaction; however, in the event that the immunochemical reaction does not take place, no spontaneous agglutination occurs.
The object of the present invention is to provide a carrier which, in a simplified measurement of biological components based on the utilization of an immunochemical agglutination reaction or an agglutination inhibition reaction, gives a high sensitivity and specificity comparable to that of Radioimmunoassay.
The present invention relates to a carrier for immunochemical measurement characterized in that tannic acid is bound to blood cells in a proportion of 30 to 500 mg per 1 ml of blood cells. Heretofore, the qualitative and quantitative measurements of the biological components of a living body have been carried out by utilizing immunochemical reactions. Although these methods were quite simple as compared with radioimmunoassay (RIA method), they have drawbacks in that an antigen-antibody reaction has produced a low sensitivity and specificity as compared with the said RIA method because no one could find a suitable carrier for carrying antigen and antibody which reacts with biological components through an immunochemical reaction.
As a consequence of the investigation by the present inventors, it was found, by mixing the blood cells with a large quantity of tannic acid, that a carrier consisting of blood cells in which 30 to 500 mg of tannic acid is bound to 1 ml of blood cells, shows extremely superior properties in immunochemical measurements.
The carrier of the present invention is usually prepared by mixing and reacting a blood cell suspension containing 2 to 4% blood cells in a buffer solution with a solution of tannic acid in the said buffer solution at a concentration of 1/50 to 1/1,000 tannic acid, so that 30 to 500 mg of tannic acid is bound to 1 ml of the blood cells.
The blood cells used in the present invention may be of any type which has been used as a carrier for conventional immunochemical measurements.
The quantity of tannic acid to be bound to blood cells is preferably in the range of 30 to 500 mg per 1 ml of the blood cells. If the quantity is less than 30 mg, the carrier cannot achieve the desired high sensitivity and specificity. If it exceeds 500 mg, the carrier has too intense an agglutination property to be controlled by the method hereinafter described, and therefore the carrier can no longer be used in an immunochemical measurement.
Usually, in the reaction between blood cells and tannic acid, equal quantities of blood cell suspension containing 2 to 4% blood cells and a tannic acid solution having a concentration of 1/50 to 1/1,000 are mixed; however, the concentration of blood cells in the suspension, the concentration of tannic acid in the tannic acid solution and the mixing ratio of the blood cell suspension and the tannic acid solution are made so that the quantity of tannic acid bound to 1 ml of blood cells may be in the range of 30 to 500 mg. That is to say, this is done either by suspending blood cells in a tannic acid solution of 1/100 to 1/2,000 concentration or by adding tannic acid itself to a blood cell suspension of 1 to 2% concentration.
The buffer solution to suspend blood cells and dissolve tannic acid may be any type of buffer solution conventionally used in an immunochemical reaction, and moreover, a physiological saline solution can be used, preferably a phosphate-buffer saline solution.
Although the blood cells may be reacted with tannic acid at room temperature, better results are obtained by heating at a temperature ranging from 37° to 56° C, which is the usual temperature range adopted in general immunochemical processes.
As a result of the present carrier retaining a larger quantity of tannic acid than the conventional carriers, the agglutination property of the carrier itself is much enhanced and at the same time, it can bind a larger quantity of antigen or antibody to itself than the conventional carriers.
The relation between the quantity of tannic acid which has been added for treating blood cells and the quantity of tannic acid bound to the blood cells is shown in Table 1.
TABLE 1
______________________________________
Quantity of Tannic acid
tannic acid bound to 1
added to 1 ml
ml of blood Rate of
of blood cells
cells Binding
(mg) (mg) (%)
______________________________________
1 0.94 94.0
10 8.82 88.2
100 86.2 86.2
600 498 83.0
______________________________________
The values shown in Table 1 are those of tannic acid measured with Folin-Denis reagent in ethanol extracts from the blood cells treated with tannic acid. About the same values are also obtained by measuring the residual tannic acid content in the supernatant after the blood cells are bound with tannic acid and deducing it from the initial quantity of tannic acid. From this table, a majority of the added tannic acid is found to be bound to blood cells regardless of the quantity of tannic acid added to blood cells.
Next, studies have been made on the agglutination property of the carrier itself, the agglutination property when bovine serum albumin is added as the stabilizer for a reaction system, and the agglutination property of a carrier sensitized with anti-HSA antibody to compare the conventional carriers with the present carrier. The agglutination property of a carrier itself generally varies with pH and ionic strength, etc., of the buffer solution in which the carrier is suspended. In the present example, carriers bound with various quantities of tannic acid are suspended in a phosphate buffer saline solution (pH 6.4 and concentration 0.076 Mol) at a concentration of 0.133%, and 0.5 ml of each suspension is placed in a small test tube and allowed to stand for two hours, after which the agglutination property of the carrier is evaluated on the basis of the sedimentation patterns at the bottom of the tube.
The agglutination property of a carrier itself, with the addition of bovine serum albumin as a stabilizer for a reaction system, is measured in the same manner as in the absence of the serum albumin, except that a phosphate-buffer saline solution containing 0.2% bovine serum albumin is used for suspending the carrier. The agglutination property of a carrier sensitized with an anti-HSA antibody is measured in the same manner as in Column 2 of Table 2, except that the carrier sensitized with the anti-HSA antibody is used. The criteria for sedimentation patterns at the bottom of a test tube are set according to the following:
+++ Very intense positive reaction p1 ++ Intense positive reaction
+ Positive reaction
- Negative reaction
The results are summarized in Table 2.
TABLE 2
______________________________________
Column 1
Column 2 Column 3
Agglutination
property of
carrier itself
with the addi-
Agglutination
Tannic Aggluti- tion of bovine
property of
acid bound
nation serum albumin
carrier
to 1 ml of
property as a stabilizer
sensitized with
blood cells
of carrier
for reaction an anti-HSA
(mg) itself system antibody
______________________________________
500 +++ ++ -
100 +++ + -
10 ++ - -
1 - - -
______________________________________
Table 2 shows that the carrier of the present invention bound with a large quantity of tannic acid brings about a spontaneous agglutination reaction, while the conventional carriers bound with only a small quantity of tannic acid do not. This suggests that the bonding of blood cells with a large quantity of tannic acid leads to occurrence of a certain change on the surface of blood cells which brings about an increase in the agglutination property of the carrier itself.
The relation between the quantity of tannic acid bound to blood cells and the quantity of antibody or antigen bound to the carrier which combines with tannic acid was also studied.
The quantity of antibody or antigen bound to a carrier is measured through determination of the quantity of antibody or antigen remaining in the supernatant after the sensitization of the carrier with antibody or antigen by an immunological diffusion method, and deducing it from the initial quantity of antibody or antigen added for the purpose of sensitization.
In the present example, a rabbit gamma globulin and HSA are respectively used as antibody and antigen.
The results are summarized in Table 3.
TABLE 3
______________________________________
bound antibody
(gamma globulin)
Tannic acid bound
(mg) Bound antigen (HSA)
to 1 ml of blood
(5mg addition to
(mg)
cells 0.2 ml blood (2mg adition to
(mg) cells) 0.2 ml blood cells)
______________________________________
500 3.0 (60%) 1.7 (85%)
100 2.5 (50%) 2.5 (75%)
50 1.9 (38%) 1.3 (65%)
10 0.6 (12%) 0.7 (35%)
1 0.4 ( 8%) 0.3 (15%)
______________________________________
As is obvious from Table 3, the more bound tannic acid a carrier has, the more gamma globulin it has to be bound to said carrier, and a carrier bound with 500 mg tannic acid per 1 ml of blood cells binds about 7.5 times as much gamma globulin as that bound with 1 mg tannic acid. The situation is similar in the case of the quantity of bound antigen. In conclusion, the carrier of the present invention has a remarkably increased potency to bind antibody or antigen as compared with the conventional carriers.
In addition, the carrier of the present invention has the advantage that the high agglutination property and potency to bind a large quantity of antigen or antibody can be controlled in accordance with the purpose of application. Such control is most effectively made in applying the known art most advantageously, e.g., in the sensitization of a carrier with antigen or antibody so as to control the quantity of antigen or antibody, the addition of normal rabbit albumin, bovine serum albumin or a surfactant etc. as stabilizer for the immunochemical reaction system, the control of pH and ionic strength of the immunochemical reaction system, or the combination of this well known art. (See Table 2)
The carrier of the present invention can be used as a carrier for antigen or antibody in the immunochemical agglutination and agglutination inhibition reactions. For instance, when HSA is measured by using the present carrier, the measurement of 100 pg/ml order of HSA is possible. That is to say, the sensitivity of the measurement is enhanced about 1,000 times as compared with the use of conventional carriers.
The following Experiments and Examples will concretely illustrate the present invention.
2 ml of sheep blood cells fixed with formalin was suspended in 60 ml of phosphate-buffer saline solution. The suspension was mixed with 60 ml of a solution of tannic acid of varied concentrations dissolved in the said buffer solution, and the mixture was reacted at 56° C for 30 minutes. Thus, several carriers with the varied bound quantities of tannic acid were obtained. Each of the carriers was suspended in 60 ml of the said buffer solution and was then mixed with antibody solution prepared by dissolving 60 mg of an anti-HSA antibody (as rabbit gamma globulin) into the said buffer solution. The mixture was reacted at 56° C for 30 minutes until the carrier was sensitized with the anti-HSA antibody. Thereafter each of the sensitized carriers thus obtained was washed with 50 ml of buffer solution, and prepared into a 1% suspension in a phosphate buffer saline solution containing 10% of sucrose, 0.1% of bovine serum albumin and 0.02% of normal rabbit serum.
0.1 ml of each of the sensitized carrier suspensions was placed in a test tube of an inner diameter of about 9mm having a hemispherical bottom and mixed gradually with 0.3 ml of the phosphate buffer saline solution to give a 0.25% suspension, followed by the additions of 0.1 ml of HSA solutions respectively with 0.05, 0.1, 0.2, 0.5, 1.0, 2.0, 5.0 10, 20, 50 or 100 ng/ml of HSA. After shaking, the mixtures were allowed to stand for 2 hours. The sedimentation patterns developed at the bottom of the test tubes were observed, and the results were judged as negative and positive respectively according to whether a sedimentation ring was formed or not.
Table 4 illustrates the results of sensitivities of various carriers exhibited in the HSA measurements as represented in terms of the minimum quantities of HSA necessary for giving positive reactions.
TABLE 4
______________________________________
Concentration
of tannic acid
Tannic acid Sensitivity
solution used
bound to 1 ml in HSA
for treating
of blood cells measurement
blood cells (mg) (ng/ml)
______________________________________
1/50 500 *(498) 0.5
1/250 100 (103) 0.1
1/900 30 (29) 5.0
1/2,500 10 (10.4) 20
1/30,000 1 (0.96) 100
______________________________________
*The parenthesized figures are actually measured values.
As evident from Table 4, the best result was obtained with the carrier wherein 100 mg of tannic acid is bound to 1 ml of blood cells. This carrier exhibited about 1,000 times as great sensitivity as the conventional one wherein only 1 mg of tannic acid is bound to 1 ml of blood cells.
60 ml of each of the carrier suspensions prepared in the same manner as in Experiment 1 was mixed with a solution of 6 mg of 2,4-dinitrophenol-bovine serum albumin combination product (hereinafter referred to as DNP-BSA) in 60 ml of phosphate buffer saline solution, and the solution was reacted at 56° C for 30 minutes until the carrier was sensitized with DNP-BSA. Then each of the carriers was washed with 50 ml of the above-mentioned buffer solution and prepared into 1% suspension in the phosphate buffer saline solution containing 10% of sucrose, 0.1% of bovine serum albumin and 0.02% of normal rabbit serum.
With the sensitized carriers, the maximum dilution ratio of anti-serum necessary for the occurrence of an agglutination reaction of the carriers was studied first.
An anti-DNP-BSA anti-serum was prepared by mixing Freund's Complete Adjuvant with DNP-BSA by a conventional method and thereby immunizing rabbits. The absorption of the serum with BSA yielded an anti-serum which exhibited an antibody activity only to DNP. The anti-serum was diluted with 0.25% saline solution containing 1% BSA in the order of 1, 10, 20, 50, 100, 200, 300, 400, and 500 times. Then, 0.1 ml of the diluted serums was added to a test tube which contained 0.1 ml of each of the said sensitized carrier suspensions and 0.3 ml of phosphate buffer saline solution and shaken. After allowing to stand for 2 hours, the maximum dilution ratio of anti-serum necessary for the occurrence of an agglutination reaction of the carriers was determined.
Next, some agglutination inhibition systems were composed between each of the sensitized carriers and the anti-serum determined at the maximum dilution ratio necessary for the agglutination reaction. Each of the systems thus obtained was investigated for its sensitivity in the DNP measurement.
For each of the agglutination inhibition reaction systems, 0.1 ml of the said anti-serum of maximum dilution was mixed in a test tube with 0.1 ml of a DNP solution containing 50, 100, 200, 300, 500, 700 or 1,000 ng/ml of DNP in phosphate buffer saline solution, to which were added 0.1 ml of said sensitized carrier suspension and 0.2 ml of phosphate buffer saline solution. After shaking and allowing to stand for 2 hours, the sedimentation pattern developed on the bottom of the test tube was observed. In the case of a sedimentation ring being formed, the result was judged as positive, while it was judged as negative when a sedimentation ring was not formed.
The sensitivities of the carriers are summarized in Table 5, being represented in terms of the minimum quantities of DNP necessary for the occurrence of positive reactions.
TABLE 5
______________________________________
Maximum ratio
concentration
of dilution of
of tannic Tannic acid
anti-serum
acid solution
bound to necessaray for
Sensitivity
used for 1 ml of the occurrence
in the DNP
treating blood cell of agglutina-
measurement
blood cell
(mg) tion reaction
(ng/ml0
______________________________________
1/50 500 300 100
1/250 100 300 100
1/900 30 100 200
1/2,500 10 50 1,000
1/30,000 1 * --
______________________________________
*No agglutination occurs even when the undiluted serum is used.
As shown in Table 5, although the conventional carriers bound with 1 mg tannic acid per 1 ml of blood cell cannot be agglutinated even when the undiluted anti-serum is used, the carrier of the present invention bound with 100 mg tannic acid per 1 ml of blood cell can bring about an agglutination reaction with the anti-serum diluted three hundred fold.
The carrier of the present invention exhibited 5 to 10 times higher sensitivity in the measurement than the conventional carriers.
It is known from these experiments that the use of the carrier of the present invention in an immunochemical agglutination inhibition reaction enables the realization of a high magnification of dilution of anti-serum as compared with the case of conventional carriers, and therefore measurement of higher sensitivity is possible enabling the use of anti-serums of low antibody titer which have hitherto been impossible.
30 ml of sheep blood cells fixed with formaline was washed with 300 ml of phosphate buffer saline solution and then suspended into the buffer solution making the total volume of the solution 900 ml. To the suspension was added 900 ml of a tannic acid solution of 1/300 concentration dissolved in the said buffer solution, and the mixture was reacted at 56° C for 30 minutes. After the reaction, the carrier was twice washed with 600 ml of the buffer solution each time. The carrier in this example has about 90 mg of tannic acid per 1 ml of blood cells bound to itself.
50 ml of chicken blood cells fixed with pyruvinaldehyde was washed with ten times the physiological salt solution and then again suspended into 1,000 ml of the said solvent.
The said blood cell suspension was mixed with 2,000 ml of a tannic acid solution of 1/350 concentration and the mixture was reacted at 25° C for 60 minutes. After the reaction the carrier was washed with 1,000 ml of the said solvent. The carrier in this Example was bound with about 100 mg of tannic acid per 1 ml of blood cells.
50 ml of rabbit blood cells fixed after treatment with hydrogen peroxide was washed with 500 ml of borate buffer saline solution and then again suspended into the said buffer solution. The suspension was mixed with 1,500 ml of tannic acid solution of 1/500 concentration dissolved in the said buffer solution, and the mixture was reacted at 56° C for 45 minutes. After the reaction, the product was washed with 1,000 ml of the said buffer solution to give a carrier. The carrier in this Example takes about 50 mg of tannic acid per 1 ml of blood cell.
30 ml of untreated bovine blood cells was washed with 500 ml of veronal buffer solution, after which the blood cells were centrifuged. The blood cells were suspended into a tannic acid solution prepared by dissolving 1 g of tannic acid into 1,000 ml of the said buffer solution, and the suspension was reacted at 37° C for 30 minutes. After the reaction, the product was washed with the said buffer solution to give a carrier.
The carrier in this Example has about 30 mg of tannic acid per 1 ml of blood cells.
20 ml of bovine blood cells fixed with hydrogen peroxide was washed with 300 ml of phosphate buffer saline solution and then suspended into the said buffer solution making the total volume of the solution 600 ml.
The said blood suspension was mixed with a solution of tannic acid 1/50 concentration dissolved in the said buffer solution, and the mixture was reacted at 56° C for 30 minutes. After the reaction, the product was washed with the said buffer solution to give a carrier. The carrier in this Example contains about 500 mg of tannic acid per 1 ml of blood cells.
As mentioned above, the carrier of the present invention for immunochemical measurements has a higher sensitivity and higher specificity as compared with conventional carriers so that it easily brings about an immunochemical reaction even when the quantity of biological components is very small, and based on this reaction, it shows a complete agglutination reaction. Therefore, the use of the carrier of the present invention facilitates the measurement of biological components affording itself a very high medical value.
Claims (14)
1. A reaction system for immunochemical measurement comprising a carrier containing blood cells which are bound to tannic acid in a quantity of 30 to 500 mg of tannic acid per 1 ml of the blood cells, said carrier being sensitized with an antigen or antibody.
2. A reaction system for immunochemical measurement according to claim 1, wherein the blood cells are obtained from at least one animal in an untreated state.
3. A reaction system for immunochemical measurement according to claim 1 which has additionally been adapted in accordance with the purpose of measurement by adding a stabilizer.
4. A reaction system for immunochemical measurement according to claim 1 which has additionally been adapted in accordance with the purpose of measurement by controlling its pH.
5. A reaction system for immunochemical measurement according to claim 1 which has additionally been adapted in accordance with the purpose of measurement by controlling its ionic strength.
6. A method for measuring immunochemical biological components which comprises the step of bringing the reaction system of claim 1 into an immunochemical agglutination or agglutination inhibition reaction with a test sample containing the biological components to be measured.
7. A carrier for immunochemical measurement according to claim 1, wherein blood cells are obtained from at least one animal and fixed with an appropriate fixing agent.
8. A carrier according to claim 7 wherein the appropriate fixing agent is selected from the group consisting of formaldehyde, pyruvicaldehyde and hydrogen peroxide.
9. A process for preparing a reaction system for immunochemical measurement comprising blood cells which are bound to tannic acid in the proportion of 30 to 500 mg of tanic acid per 1 ml of the blood cells and an antigen or antibody, which process comprises the steps of reacting a blood cell suspension prepared by suspending blood cells in a buffer solution with a tannic acid solution, the concentrations and mixing ratio of said solutions being such as to bind 30 to 500 mg of tannic acid to 1 ml of blood cell to provide a carrier, and then sensitizing said carrier with an antigen or antibody.
10. A process according to claim 9, wherein a blood cell suspension with a blood cell concentration of 2 to 4% in a buffer solution is mixed and reacted with a solution containing tannic acid dissolved in the same buffer solution at a concentration of 1/50 to 1/1,000 so that 30 to 500 mg of tannic acid is bound to 1 ml of blood cells.
11. A process according to claim 9, wherein the blood cells to be used are selected from the group consisting of natural blood cells obtained from animals and fixed blood cells obtained by fixing natural blood cells with a fixing agent.
12. A process according to claim 9, wherein said reaction temperature is in the range of 37° to 56° C.
13. A process for preparing a reaction system for immunochemical measurement comprising blood cells which are bound to tannic acid in a proportion of 30 to 500 mg of tannic acid per 1 ml of the blood cells, which process comprises the steps of reacting blood cells and tannic acid in a buffer solution so that 30 to 500 mg of tannic acid is bound to each ml of blood cells to form a carrier and then sensitizing said carrier with an antigen or antibody.
14. A process according to claim 13, wherein the buffer solution is selected from the group consisting of phosphate buffer saline solution, physiological salt solution, borate buffer saline solution, or veronal buffer solution.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP49132175A JPS5247012B2 (en) | 1974-11-16 | 1974-11-16 | |
| JA49-132175 | 1974-11-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US4062936A true US4062936A (en) | 1977-12-13 |
Family
ID=15075116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US05/628,344 Expired - Lifetime US4062936A (en) | 1974-11-16 | 1975-11-03 | Carrier for immunochemical measurement |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US4062936A (en) |
| JP (1) | JPS5247012B2 (en) |
| BR (1) | BR7507475A (en) |
| CA (1) | CA1049404A (en) |
| DE (1) | DE2551576C3 (en) |
| DK (1) | DK143045C (en) |
| FR (1) | FR2291496A1 (en) |
| GB (1) | GB1487698A (en) |
| NL (1) | NL180546C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4200434A (en) * | 1977-02-24 | 1980-04-29 | Sanki Engineering Ltd. | Immunological blood test method |
| US4321058A (en) * | 1979-06-28 | 1982-03-23 | Seikagaku Kogyoco Ltd. | Latex composition and method for determining erythropoietin |
| EP0176780A1 (en) * | 1984-08-31 | 1986-04-09 | Shionogi & Co., Ltd. | A preservative solution for fixed avian erythrocytes for the viral hemagglutination test |
| EP0317085A3 (en) * | 1987-10-20 | 1989-09-20 | Sumitomo Seika Chemicals Co., Ltd. | Processed red blood cells and process for producing the same |
| US5589463A (en) * | 1985-10-10 | 1996-12-31 | Biotechnology Autralia Pty., Ltd. | Oral delivery of biologically active substances bound to vitamin B12 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5341420A (en) * | 1976-09-29 | 1978-04-14 | Mochida Pharm Co Ltd | Immunochemically measuring methoa of hapten |
| JPS5512419A (en) * | 1978-07-13 | 1980-01-29 | Teikoku Hormone Mfg Co Ltd | Immunological measurement and reagent therefor |
| FR2475737A1 (en) * | 1980-02-07 | 1981-08-14 | Pasteur Institut | Preservation of red blood corpuscles - suitable for use as haemagglutination standards, by aldehyde treatment and lyophilisation |
| GB2138132B (en) * | 1983-04-12 | 1987-02-18 | Robin Royston Amos Coombs | Storage-stable antibody-linked erythrocytes |
| CN112089832B (en) * | 2020-09-25 | 2022-04-22 | 江南大学 | A hapten-modified carrier protein and its application in the preparation of vaccines |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1210819A (en) * | 1966-11-08 | 1970-11-04 | Organon Labor Ltd | Immunochemical determinations of antigens and antibodies |
| US3574137A (en) * | 1969-02-25 | 1971-04-06 | Pfizer | Multiple-analysis hematology control comprising human red blood cells and fowl red blood cells in an anticoagulant containing human serologically compatible plasma medium |
| US3607783A (en) * | 1967-11-08 | 1971-09-21 | Antonio Tata | Solution for preserving microscopic corpuscles |
| US3715427A (en) * | 1967-11-13 | 1973-02-06 | Abbott Lab | Stabilized erythrocytes and methods therefor |
-
1974
- 1974-11-16 JP JP49132175A patent/JPS5247012B2/ja not_active Expired
-
1975
- 1975-10-30 GB GB45036/75A patent/GB1487698A/en not_active Expired
- 1975-11-03 US US05/628,344 patent/US4062936A/en not_active Expired - Lifetime
- 1975-11-12 BR BR7507475*A patent/BR7507475A/en unknown
- 1975-11-13 NL NLAANVRAGE7513302,A patent/NL180546C/en not_active IP Right Cessation
- 1975-11-14 CA CA239,698A patent/CA1049404A/en not_active Expired
- 1975-11-14 FR FR7534767A patent/FR2291496A1/en active Granted
- 1975-11-14 DK DK513375A patent/DK143045C/en not_active IP Right Cessation
- 1975-11-17 DE DE2551576A patent/DE2551576C3/en not_active Expired
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1210819A (en) * | 1966-11-08 | 1970-11-04 | Organon Labor Ltd | Immunochemical determinations of antigens and antibodies |
| US3607783A (en) * | 1967-11-08 | 1971-09-21 | Antonio Tata | Solution for preserving microscopic corpuscles |
| US3715427A (en) * | 1967-11-13 | 1973-02-06 | Abbott Lab | Stabilized erythrocytes and methods therefor |
| US3574137A (en) * | 1969-02-25 | 1971-04-06 | Pfizer | Multiple-analysis hematology control comprising human red blood cells and fowl red blood cells in an anticoagulant containing human serologically compatible plasma medium |
Non-Patent Citations (1)
| Title |
|---|
| Gradwohl's Clinical Laboratory Methods & Diagnosis, vol. 2, Mosby & Co., St. Louis (1970), pp. 1559-1560. * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4200434A (en) * | 1977-02-24 | 1980-04-29 | Sanki Engineering Ltd. | Immunological blood test method |
| US4321058A (en) * | 1979-06-28 | 1982-03-23 | Seikagaku Kogyoco Ltd. | Latex composition and method for determining erythropoietin |
| EP0176780A1 (en) * | 1984-08-31 | 1986-04-09 | Shionogi & Co., Ltd. | A preservative solution for fixed avian erythrocytes for the viral hemagglutination test |
| US5589463A (en) * | 1985-10-10 | 1996-12-31 | Biotechnology Autralia Pty., Ltd. | Oral delivery of biologically active substances bound to vitamin B12 |
| EP0317085A3 (en) * | 1987-10-20 | 1989-09-20 | Sumitomo Seika Chemicals Co., Ltd. | Processed red blood cells and process for producing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| GB1487698A (en) | 1977-10-05 |
| FR2291496B1 (en) | 1980-01-11 |
| DE2551576B2 (en) | 1977-11-10 |
| NL180546B (en) | 1986-10-01 |
| NL180546C (en) | 1987-03-02 |
| DK513375A (en) | 1976-05-17 |
| NL7513302A (en) | 1976-05-18 |
| DE2551576C3 (en) | 1978-06-29 |
| JPS5247012B2 (en) | 1977-11-29 |
| JPS5157818A (en) | 1976-05-20 |
| BR7507475A (en) | 1976-08-10 |
| FR2291496A1 (en) | 1976-06-11 |
| DK143045B (en) | 1981-03-16 |
| CA1049404A (en) | 1979-02-27 |
| DE2551576A1 (en) | 1976-05-20 |
| DK143045C (en) | 1981-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3551555A (en) | Coated immunochemical reagent particles and process of preparation | |
| US3714345A (en) | Stabilized erythrocyees and methods therefore | |
| US4048298A (en) | Solid phase double-antibody radioimmunoassay procedure | |
| US4433059A (en) | Double antibody conjugate | |
| US4248965A (en) | Immunochemical process of measuring physiologically active substances | |
| US4092408A (en) | Method for solid phase immunological assay of antigen | |
| JPS6411148B2 (en) | ||
| US4062936A (en) | Carrier for immunochemical measurement | |
| JPH02226067A (en) | Enzyme immunoassay for measuring concentration of in whole blood sample | |
| US4088746A (en) | Radioimmunoassay for thyroid-stimulating hormone (TSH) | |
| CA1168580A (en) | Immunological reagent for the detection of tubes of the rheumatoid factor in a biological specimen and process for preparing this novel reagent | |
| JPS6112547B2 (en) | ||
| GB1589107A (en) | Immunologic compositions | |
| US4052504A (en) | Assay for thyroxine binding globulin | |
| HU179956B (en) | Process for the immunological determination of antigens by means of enzyme marking | |
| JPH0467150B2 (en) | ||
| SU1704090A1 (en) | Method for preparing erythrocytar diagnosticum for inmmunoanalysis | |
| Másson et al. | Chemical activation of nitrocellulose membranes for peptide antigen‐antibody binding studies: direct substitution of the nitrate group with diaminoalkane | |
| Pal | Immunoassay Technology. Vol. 2 | |
| US4066410A (en) | Thyroid hormone assay | |
| Feigen et al. | Effect of antibody concentration and temperature upon physical adsorption and histamine release | |
| JPS59125064A (en) | Method for detecting hemoglobin in fece using immunological latex clotting reaction and reagent to be used for said method | |
| CA1073351A (en) | Competitive thyroid hormone radio assay in a single tube | |
| SU1158029A3 (en) | Method of quantitative determination of triiodothyronine | |
| EP0139526A2 (en) | An insolubilized stable specific binding protein |